<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-28T15:23:27Z</responseDate><request verb="GetRecord" identifier="oai:docta.ucm.es:20.500.14352/98371" metadataPrefix="rdf">https://docta.ucm.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:docta.ucm.es:20.500.14352/98371</identifier><datestamp>2025-03-18T15:53:07Z</datestamp><setSpec>com_20.500.14352_14</setSpec><setSpec>col_20.500.14352_15</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:docta.ucm.es:20.500.14352/98371">
      <dc:title>C60-based Multivalent Glycoporphyrins Inhibit SARS-CoV-2 Specific Interaction with the DC-SIGN Transmembrane Receptor</dc:title>
      <dc:creator>Patino Alonso, Jennifer</dc:creator>
      <dc:creator>Cabrera González, Justo Enrique</dc:creator>
      <dc:creator>Merino Gracia, Javier</dc:creator>
      <dc:creator>Nieta Ortiz, Gema</dc:creator>
      <dc:creator>Katati, Jouma</dc:creator>
      <dc:creator>Bezerra Da Cruz, Carlos</dc:creator>
      <dc:creator>Mateos Gil, Pablo</dc:creator>
      <dc:creator>Canales Mayordomo, María Ángeles</dc:creator>
      <dc:creator>López Montero, Iván</dc:creator>
      <dc:creator>Illescas Martínez, Beatriz María</dc:creator>
      <dc:creator>Delgado Vázquez, Rafael</dc:creator>
      <dc:creator>Martín León, Nazario</dc:creator>
      <dc:description>Since WHO has declared the COVID-19 outbreak a global pandemic, nearly seven million deaths have been reported. This efficient spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is facilitated by the ability of the spike glycoprotein to bind multiple cell membrane receptors. Although ACE2 is identified as the main receptor for SARS-CoV-2, other receptors could play a role in viral entry. Among others, C-type lectins such as DC-SIGN are identified as efficient trans-receptor for SARS-CoV-2 infection, so the use of glycomimetics to inhibit the infection through the DC-SIGN blockade is an encouraging approach. In this regard, multivalent nanostructures based on glycosylated [60]fullerenes linked to a central porphyrin scaffold have been designed and tested against DC-SIGN-mediated SARS-CoV-2 infection. First results show an outstanding inhibition of the trans-infection up to 90%. In addition, a deeper understanding of nanostructure-receptor binding is achieved through microscopy techniques, high-resolution NMR experiments, Quartz Crystal Microbalance experiments, and molecular dynamic simulations.</dc:description>
      <dc:date>2024-02-02T14:52:07Z</dc:date>
      <dc:date>2024-02-02T14:52:07Z</dc:date>
      <dc:date>2023</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>Patino‐Alonso, Jennifer, et al. «C 60 ‐based Multivalent Glycoporphyrins Inhibit SARS‐CoV‐2 Specific Interaction with the DC‐SIGN Transmembrane Receptor». Small, vol. 20, n.o 19, mayo de 2024, p. 2307045. https://doi.org/10.1002/smll.202307045.</dc:identifier>
      <dc:identifier>1613-6810</dc:identifier>
      <dc:identifier>10.1002/smll.202307045</dc:identifier>
      <dc:identifier>https://hdl.handle.net/20.500.14352/98371</dc:identifier>
      <dc:identifier>https://doi.org/10.1002/smll.202307045</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>open access</dc:rights>
      <dc:publisher>Wiley</dc:publisher>
   </ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>